BioNTech Enters Earnings Call With Revenue Forecast of €1.6 Billion to €1.9 Billion
Key Facts
BioNTech scheduled its third-quarter earnings call for November 3, 2026, according to its published investor calendar. Its latest announced full-year revenue range was €1.6–€1.9 billion, after the company cut it in August from €2.0–€2.3 billion. These figures provide context for tracking third-quarter results; the information documented here does not include a confirmed quarterly revenue figure or a new forecast update. The company said in August that the revision reflected "weaker-than-expected global demand for COVID-19 vaccines." It also cited delayed revenue tied to a research and development program licensed to another party.
Second-quarter 2026 revenue was €105.6 million, compared with €260.8 million in the second quarter of 2025. BioNTech attributed the decline in revenue for the quarter and first half, compared with the corresponding periods, mainly to lower demand for its COVID-19 vaccines. The comparison puts the effect of vaccine demand at the center of the financial picture ahead of the third-quarter call. In the third quarter of 2025, the company recorded revenue of €1.5189 billion, compared with €1.2448 billion in the same period of 2024. It said the increase was mainly related to revenue from its collaboration with Bristol Myers Squibb, recorded in the third quarter, partly offset by lower sales of COVID-19 vaccines.
In oncology, BioNTech announced on October 22 that the trial of pumitamig with sacituzumab govitecan for triple-negative breast cancer would advance to Phase 3. The development is part of the company's therapeutic program, but by itself does not show that oncology treatments generated commercial revenue or prompted a change to the 2026 forecast. In March, the company had forecast six late-stage data readouts during 2026 across programs involving immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies. On the vaccine side, BioNTech announced in August that its updated COVID-19 vaccine targeting the XFG variant had received approval from the U.S. Food and Drug Administration. These developments remain separate background to the revenue range the company announced in August.
BioNTech has scheduled its fourth-quarter and full-year 2026 earnings call for March 2, 2027, according to its financial calendar. That call will provide a later opportunity to present full-year results, following the third-quarter call scheduled for November 3, 2026. The 2026 revenue range announced in August remains €1.6 billion to €1.9 billion, compared with the previous range of €2.0–€2.3 billion. The company linked the August cut to weaker global demand for COVID-19 vaccines and delayed revenue tied to a licensed research and development program. These earlier forecasts and their context therefore remain a chronological reference point for reading the company's next financial disclosure.